RxDoctor Payments Data

Carol Counts Robinson, PhD

Psychiatric/Mental Health · Framingham, MANPI 1558679050

Payments from drug & device makers

$2,299in general payments, 2019–2025

Across 145 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$380
  • Teva Pharmaceuticals USA, Inc.$368
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$345
  • Otsuka America Pharmaceutical, Inc.$218
  • Johnson & Johnson$206
  • Neurocrine Biosciences, Inc.$172
  • plus $610 from 6 others

What the payments were for

  • Food & beverage$2,15994%
  • Education$1406%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,299 in reported general payments places this provider in the 85th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$25,125
Medicare patients
68
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate45$358,456
VraylarCariprazine Hcl118$159,823
RexultiBrexpiprazole51$78,851
Invega SustennaPaliperidone Palmitate24$66,029
CaplytaLumateperone Tosylate12$19,904
TrintellixVortioxetine Hydrobromide24$11,885
Clozapine115$7,529
ConcertaMethylphenidate Hcl12$5,624
Aripiprazole110$4,445
Gabapentin202$3,096
Bupropion XlBupropion Hcl124$2,696
Duloxetine Hcl119$2,682
Divalproex Sodium ErDivalproex Sodium47$2,581
Perphenazine16$2,464
Methylphenidate ErMethylphenidate Hcl16$2,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$172$358,45645 claims
AbbVieVraylar$99$159,823118 claims
Otsuka America Pharmaceutical, Inc.Rexulti$218$78,85151 claims
Johnson & JohnsonInvega Sustenna, Concerta$206$71,65336 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$345$19,90412 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$146$11,88524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Framingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →